Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration
Compose a Response to This Article
Other responses
No responses have been published for this article.
